Director
Sam J. Reich
Samuel J. Reich has served as executive chairman of our board of directors since our business combination with Big Cypress Acquisition Corp in October 2021 and prior to that was Chief Executive Officer, Chief Financial Officer and a member on the board of directors of Big Cypress Acquisition Corp
Director
Eddie J. Sullivan
Eddie J. Sullivan, PhD, is our co-founder and has served as our president and Chief Executive Officer since 2014. Dr. Sullivan has served in biopharma leadership positions for more than 25 years. Prior to joining SAB, he was the CEO of Hematech, a subsidiary of Kyowa Hakko Kirin, where he led
EVP & Chief Financial Officer
Russell P. Beyer
Russell P. Beyer, MBA, CMA, has served as our Chief Financial Officer since September 2021. Mr. Beyer is a global strategic business leader, bringing more than 20 years of experience working with Fortune 100 companies in the pharmaceutical industry, such as Teva, AstraZeneca, and IPR
EVP & Chief Operating Officer
Christoph Bausch
Christoph Bausch, PhD, MBA, is our Chief Operating Officer as of May 2022, overseeing all Research & Manufacturing operations of the company. Prior to his role as COO, he served as Chief Science Officer since joining SAB in April 2017, providing leadership in all areas of Research & Development,
EVP & Chief Medical Officer
Alexandra Kropotova
Dr. Kropotova MD, MBA is our Executive Vice President & Chief Medical Officer, joining SAB in June, 2022 to lead the strategy, direction, and execution of the company’s clinical development for the entire portfolio. Dr. Kropotova is a biopharmaceutical executive with expertise in all phases of